Literature DB >> 33888007

The efficacy and tolerance of prone positioning in non-intubation patients with acute hypoxemic respiratory failure and ARDS: a meta-analysis.

Wei Tan1, Dong-Yang Xu1, Meng-Jiao Xu1, Zan-Feng Wang1, Bing Dai2, Li-Li Li2, Hong-Wen Zhao1, Wei Wang1, Jian Kang1.   

Abstract

BACKGROUND AND AIMS: The application of prone positioning with acute hypoxemic respiratory failure (AHRF) or acute respiratory distress syndrome (ARDS) in non-intubation patients is increasing gradually, applying prone positioning for more high-flow nasal oxygen therapy (HFNC) and non-invasive ventilation (NIV) patients. This meta-analysis evaluates the efficacy and tolerance of prone positioning combined with non-invasive respiratory support in patients with AHRF or ARDS.
METHODS: We searched randomized controlled trials (RCTs) (prospective or retrospective cohort studies, RCTs and case series) published in PubMed, EMBASE and the Cochrane Central Register of Controlled Trials from 1 January 2000 to 1 July 2020. We included studies that compared prone and supine positioning with non-invasive respiratory support in awake patients with AHRF or ARDS. The meta-analyses used random effects models. The methodological quality of the RCTs was evaluated using the Newcastle-Ottawa quality assessment scale.
RESULTS: A total of 16 studies fulfilled selection criteria and included 243 patients. The aggregated intubation rate and mortality rate were 33% [95% confidence interval (CI): 0.26-0.42, I2 = 25%], 4% (95% CI: 0.01-0.07, I2 = 0%), respectively, and the intolerance rate was 7% (95% CI: 0.01-0.12, I2 = 5%). Prone positioning increased PaO2/FiO2 [mean difference (MD) = 47.89, 95% CI: 28.12-67.66; p < 0.00001, I2 = 67%] and SpO2 (MD = 4.58, 95% CI: 1.35-7.80, p = 0.005, I2 = 97%), whereas it reduced respiratory rate (MD = -5.01, 95% CI: -8.49 to -1.52, p = 0.005, I2 = 85%). Subgroup analyses demonstrated that the intubation rate of shorter duration prone (⩽5 h/day) and longer duration prone (>5 h/day) were 34% and 21%, respectively; and the mortality rate of shorter duration prone (⩽5 h/day) and longer duration prone (>5 h/day) were 6% and 0%, respectively. PaO2/FiO2 and SpO2 were significantly improved in COVID-19 patients and non-COVID-19 patients.
CONCLUSION: Prone positioning could improve the oxygenation and reduce respiratory rate in both COVID-19 patients and non-COVID-19 patients with non-intubated AHRF or ARDS.The reviews of this paper are available via the supplemental material section.

Entities:  

Keywords:  acute hypoxemic respiratory failure; acute respiratory distress syndrome; meta-analysis; prone positioning

Year:  2021        PMID: 33888007     DOI: 10.1177/17534666211009407

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  3 in total

Review 1.  Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences.

Authors:  Sen Lu; Xiaobo Huang; Rongan Liu; Yunping Lan; Yu Lei; Fan Zeng; Xuemei Tang; Hongli He
Journal:  Front Med (Lausanne)       Date:  2022-05-27

2.  Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study.

Authors:  Mariano Esperatti; Marina Busico; Nora Angélica Fuentes; Adrian Gallardo; Javier Osatnik; Alejandra Vitali; Elizabeth Gisele Wasinger; Matías Olmos; Jorgelina Quintana; Santiago Nicolas Saavedra; Ana Inés Lagazio; Facundo Juan Andrada; Hiromi Kakisu; Nahuel Esteban Romano; Agustin Matarrese; Mariela Adriana Mogadouro; Giuliana Mast; Claudia Navarro Moreno; Greta Dennise Rebaza Niquin; Veronica Barbaresi; Alejandro Bruhn Cruz; Bruno Leonel Ferreyro; Antoni Torres
Journal:  Crit Care       Date:  2022-01-07       Impact factor: 9.097

3.  Awake prone positioning for patients with COVID-19 pneumonia in intensive care unit: A systematic review and meta-analysis.

Authors:  Hui-Bin Huang; Yan Yao; Yi-Bing Zhu; Bin Du
Journal:  Front Med (Lausanne)       Date:  2022-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.